問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Rheumatology

Division of Dermatology

Division of Dermatology

更新時間:2023-09-19

朱家瑜Chu, Chia-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

篩選

List

61Cases

2020-01-30 - 2025-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2021-12-01 - 2024-01-19

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-05-31 - 2027-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-10-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2019-01-23 - 2022-12-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus
  • Condition/Disease

    Pemphigus

  • Test Drug

    PRN1008

Participate Sites
3Sites

Recruiting3Sites

2018-12-13 - 2020-12-09

Phase III

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    ABT-494 (Upadacitinib)

Participate Sites
4Sites

Terminated4Sites

2018-08-31 - 2025-06-30

Phase III

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Upadacitinib

Participate Sites
4Sites

Terminated4Sites

2023-01-19 - 2026-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites